Salud financiera de hoja de balance de PolyNovo

Salud financiera controles de criterios 3/6

PolyNovo tiene un patrimonio de los accionistas total de A$69.1M y una deuda total de A$2.3M, lo que sitúa su ratio deuda-patrimonio en 3.4%. Sus activos y pasivos totales son A$97.2M y A$28.2M respectivamente.

Información clave

3.4%

Ratio deuda-patrimonio

AU$2.32m

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	AU$45.63m
Patrimonio	AU$69.05m
Total pasivo	AU$28.16m
Activos totales	AU$97.21m

Actualizaciones recientes sobre salud financiera

Recent updates

When Should You Buy PolyNovo Limited (ASX:PNV)?

Feb 28

Why Investors Shouldn't Be Surprised By PolyNovo Limited's (ASX:PNV) P/S

Feb 02

PolyNovo Limited (ASX:PNV) Shares Could Be 47% Below Their Intrinsic Value Estimate

Jan 08

Health Check: How Prudently Does PolyNovo (ASX:PNV) Use Debt?

Sep 22

When Should You Buy PolyNovo Limited (ASX:PNV)?

Jun 26

Are Investors Undervaluing PolyNovo Limited (ASX:PNV) By 29%?

May 30

Shareholders Should Be Pleased With PolyNovo Limited's (ASX:PNV) Price

Apr 18

Is It Too Late To Consider Buying PolyNovo Limited (ASX:PNV)?

Mar 23

Is PolyNovo Limited (ASX:PNV) Worth AU$2.6 Based On Its Intrinsic Value?

Feb 05

Returns At PolyNovo (ASX:PNV) Are On The Way Up

Nov 16

PolyNovo Limited's (ASX:PNV) Intrinsic Value Is Potentially 95% Above Its Share Price

Nov 01

What Does PolyNovo Limited's (ASX:PNV) Share Price Indicate?

Jul 29

PolyNovo (ASX:PNV) Is Looking To Continue Growing Its Returns On Capital

Jun 15

Estimating The Fair Value Of PolyNovo Limited (ASX:PNV)

May 16

We Think PolyNovo (ASX:PNV) Is Taking Some Risk With Its Debt

Apr 28

There's Been No Shortage Of Growth Recently For PolyNovo's (ASX:PNV) Returns On Capital

Mar 07

Is PolyNovo (ASX:PNV) Weighed On By Its Debt Load?

Dec 13

PolyNovo Limited's (ASX:PNV) CEO Compensation Looks Acceptable To Us And Here's Why

Oct 19

Is PolyNovo (ASX:PNV) Using Debt In A Risky Way?

May 08

News Flash: 7 Analysts Think PolyNovo Limited (ASX:PNV) Earnings Are Under Threat

Feb 27

Earnings Update: PolyNovo Limited (ASX:PNV) Just Reported And Analysts Are Trimming Their Forecasts

Feb 25

Is PolyNovo Limited (ASX:PNV) Potentially Undervalued?

Feb 17

These Analysts Think PolyNovo Limited's (ASX:PNV) Earnings Are Under Threat

Jan 14

Breakeven Is Near for PolyNovo Limited (ASX:PNV)

Dec 28

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (A$70.3M) de PNV superan a sus pasivos a corto plazo (A$14.0M).

Pasivo a largo plazo: Los activos a corto plazo de PNV (A$70.3M) superan a sus pasivos a largo plazo (A$14.1M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: PNV tiene más efectivo que su deuda total.

Reducción de la deuda: El ratio deuda-patrimonio de PNV ha crecido de 0% a 3.4% en los últimos 5 años.

Cobertura de la deuda: El flujo de caja operativo de PNV es negativo, por lo que la deuda no está bien cubierta.

Cobertura de intereses: Datos insuficientes para determinar si los pagos de intereses de PNV sobre su deuda están bien cubiertos por el EBIT.

Hoja de balance

Descubre empresas con salud financiera

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Salud financiera de hoja de balance de PolyNovo

Salud financiera controles de criterios 3/6

Información clave

Actualizaciones recientes sobre salud financiera

Health Check: How Prudently Does PolyNovo (ASX:PNV) Use Debt?

We Think PolyNovo (ASX:PNV) Is Taking Some Risk With Its Debt

Is PolyNovo (ASX:PNV) Weighed On By Its Debt Load?

Is PolyNovo (ASX:PNV) Using Debt In A Risky Way?

Recent updates

Now 23% undervalued

Now 20% undervalued

Price target increased by 9.7% to AU$2.14

When Should You Buy PolyNovo Limited (ASX:PNV)?

First half 2024 earnings released: EPS: AU$0.004 (vs AU$0.006 loss in 1H 2023)

Why Investors Shouldn't Be Surprised By PolyNovo Limited's (ASX:PNV) P/S

Price target increased by 7.4% to AU$1.95

PolyNovo Limited (ASX:PNV) Shares Could Be 47% Below Their Intrinsic Value Estimate

PolyNovo Limited, Annual General Meeting, Nov 03, 2023

Price target decreased by 9.5% to AU$1.88

Health Check: How Prudently Does PolyNovo (ASX:PNV) Use Debt?

Price target decreased by 7.8% to AU$2.07

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates fall by 65%, revenue upgraded

Forecast breakeven date pushed back to 2025

When Should You Buy PolyNovo Limited (ASX:PNV)?

Are Investors Undervaluing PolyNovo Limited (ASX:PNV) By 29%?

Price target decreased by 11% to AU$2.25

Forecast breakeven date pushed back to 2025

Shareholders Should Be Pleased With PolyNovo Limited's (ASX:PNV) Price

Independent Non-Executive Chairman recently sold AU$9.7m worth of stock

Is It Too Late To Consider Buying PolyNovo Limited (ASX:PNV)?

Now 23% undervalued after recent price drop

Forecast breakeven date moved forward to 2023

First half 2023 earnings released: AU$0.006 loss per share (vs AU$0.002 profit in 1H 2022)

PolyNovo Limited Announces Update on SynPath Diabetic Foot Ulcer Trial

PolyNovo Limited Announces Update on SynPath Diabetic Foot Ulcer Trial

Price target increased by 13% to AU$2.36

Consensus EPS estimates upgraded to AU$0.0002 loss

Is PolyNovo Limited (ASX:PNV) Worth AU$2.6 Based On Its Intrinsic Value?

Forecast breakeven date pushed back to 2024

Price target increased to AU$1.98

Price target increased to AU$1.90

Returns At PolyNovo (ASX:PNV) Are On The Way Up

PolyNovo Limited's (ASX:PNV) Intrinsic Value Is Potentially 95% Above Its Share Price

Independent Non-Executive Chairman recently bought AU$202k worth of stock

PolyNovo Limited, Annual General Meeting, Oct 28, 2022

PolyNovo Limited Announces Re-Designation of David McQuillan as Chief Technical and Scientific Officer

Price target increased to AU$1.68

Full year 2022 earnings: EPS misses analyst expectations

Now 21% undervalued

PolyNovo Limited Announces First Patient Enrolled in Clinical Trial of NovoSorb SynPath Treatment for Diabetic Foot Ulcers

PolyNovo Limited Announces CEO Changes

PolyNovo Limited Announces CEO Changes

What Does PolyNovo Limited's (ASX:PNV) Share Price Indicate?

Consensus forecasts updated

Now 21% undervalued

PolyNovo (ASX:PNV) Is Looking To Continue Growing Its Returns On Capital

Independent Non-Executive Chairman recently bought AU$956k worth of stock

Now 23% undervalued

Estimating The Fair Value Of PolyNovo Limited (ASX:PNV)

Independent Non-Executive Chairman recently bought AU$434k worth of stock

We Think PolyNovo (ASX:PNV) Is Taking Some Risk With Its Debt

Price target decreased to AU$1.57

Consensus forecasts updated

There's Been No Shortage Of Growth Recently For PolyNovo's (ASX:PNV) Returns On Capital

Price target decreased to AU$1.70

First half 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus forecasts updated

Price target decreased to AU$2.04

Is PolyNovo (ASX:PNV) Weighed On By Its Debt Load?

PolyNovo Limited's (ASX:PNV) CEO Compensation Looks Acceptable To Us And Here's Why

PolyNovo Limited Announces First Patient Enrolled in Pivotal Trial of the BARDA Funded Burn Study

Full year 2021 earnings released

Price target decreased to AU$2.48

PolyNovo Limited Provides an Update on its Hernia Device

Is PolyNovo (ASX:PNV) Using Debt In A Risky Way?

Non-Executive Independent Director recently sold AU$571k worth of stock

Price target increased to AU$2.92

Independent Non-Executive Chairman recently bought AU$721k worth of stock

PolyNovo Announces It has Received Final Independent Review Board